Skip to main content

Par Technology Corp(PAR-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

PR Newswire - Thu Jul 14, 2022

Key Highlights 

NEW YORK, July 14, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company) a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has entered into a corporate partnership with NFL Alumni Health (NFLAH). This partnership will inform NFL Alumni Association (NFLAA) members about osteoarthritis disease onset and progression, current treatment options, and provide information about actively enrolling clinical trials throughout the U.S.


Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.